CD274 and cancer: In addition, we further investigated the therapeutic responsiveness and clinical benefits of anti-PD-L1 immunotherapy by comparing different CSGALNACT2 expression cohorts, we found that the expression of CSGALNACT2 had no significant impact on immunotherapy in cancer patients (Fig. 6F-H).